Targeting the CtBP1-FOXM1 complex members with specific small molecule inhibitors can significantly overcome this chemoresistance, suggesting a new therapeutic option for the treatment of osteosarcoma, especially in those patients with chemoresistance. Here, CTBP1 is linked to osteosarcoma.